×

Browse

The 2nd Innovation and Biomarkers in Cancer Drug Development Conference (IBCD)

IBCD 2018 will explore routes through the constantly evolving scientific, methodological and regulatory environment for drug and biomarker development. The EORTC, NCI, EMA, and AACR with the involvement of FDA and PMDA and Health Technology Assessment specialists endeavour to build upon the recommendations and action points decided upon at the IBCD2016-edition. Topics, such as, Health Technology Assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice will be addressed.  The conference will also discuss the emergence of new regulatory routes to approve new anti-cancer agents based on biomarkers, demonstrating the relevance and feasibility of innovative clinical trial designs.

Website: http://events.eortc.org/wpmulti/ibcd/